88028445

Information

• Trademark
• 88028445

• Source

• Serial Number

  88028445

• Registration Number

  6008686

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 9 - Scientific, nautical, surveying, photographic, cinematographic, optical, weighing, measuring, signalling, checking (supervision), life-saving and teaching apparatus and instruments
  • 42 - Scientific and technological services and research and design relating thereto

• Filing Date

  July 06, 2018
  6 years ago

• Registration Date

  March 10, 2020
  4 years ago

• Transaction Date

  March 10, 2020
  4 years ago

• Status Date

  March 10, 2020
  4 years ago

• Published for Opposition Date

  June 18, 2019
  5 years ago

• Location Date

  February 04, 2020
  4 years ago

• First Use Anywhere Date

  November 08, 2019
  5 years ago

• First Use In Commerce Date

  November 08, 2019
  5 years ago

• Status Code

  700

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  BRADLEY, EVELYN W

• Attorney Docket Number

  107541-0038

  Attorney Name

  Rachelle A. Dubow, Esq.

  Law Office Assigned Location Code

  L40

• Owners

  • FACTOR BIOSCIENCE INC.

Case File Statements

• CC0000: Color is not claimed as a feature of the mark.
• DM0000: The mark consists of a stylized helix design.
• GS0011: Biochemicals in the nature of synthetic RNA encoding natural or engineered nucleases, zinc-finger nucleases, meganucleases, nickases, and transcription activator-like effector nucleases for use in vivo and in vitro genetic engineering
• GS0051: Pharmaceuticals for treating human and veterinary non-infectious diseases in the nature of inflammatory diseases, infectious diseases, vitamin B12 deficiency, degenerative joint diseases, sensory organ diseases, hereditary diseases, namely, genetic diseases in the nature of chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, psychological diseases and physiological diseases in the nature of heart disease; gene therapy products, namely, genetically engineered cells and tissues for medical purposes, specifically for transplant purposes; chemical reagents for medical and veterinary purposes; synthetic mRNA being nucleic acid sequences and chemical reagents for medical and veterinary purposes for correcting deficient or defective genes; cell therapy products, namely, pharmaceutical preparations for use in cell therapy for treatment of cancer; synthetic mRNA being nucleic acid sequences and related chemical reagents for medical and veterinary purposes for reprogramming cells; synthetic RNA encoding reprogramming factors, namely, pharmaceutical preparations for use in cell therapy for treatment of wounded skin, cancer, chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, and heart disease; products in the nature of pharmaceutical preparations for use in cell therapy for converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing, for treatment of wounded skin, cancer, chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, and heart disease
• GS0091: Gene therapy technology in the nature of downloadable software for gene-editing that uses de novo-engineered gene-editing proteins expressed with synthetic mRNA; cell therapy products, namely, cell reprogramming technology in the nature of instruments for scientific laboratory research that use reprogramming factors expressed with synthetic mRNA, namely, cell-culture instruments in the nature of cell incubators, cell transfection instruments, and cell imaging instruments
• GS0421: Pharmaceutical research and development services; pharmaceutical research and development services in the field of production of cell therapies, with or without gene-editing and with or without mRNA engineering; pharmaceutical research and development services in the field of, gene editing, mRNA engineering, cell reprogramming and cell therapy development; scientific laboratory services, in the field of stem cell production; scientific laboratory services in the field of production of stem cells and converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing; scientific laboratory services in the field of gene-editing

Case File Event Statements

• 3/10/2020 - 4 years ago

  30 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 2/5/2020 - 4 years ago

  29 - NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Type: SUNA

• 2/4/2020 - 4 years ago

  28 - ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Type: CNPR

• 12/29/2019 - 4 years ago

  27 - STATEMENT OF USE PROCESSING COMPLETE Type: SUPC

• 12/18/2019 - 4 years ago

  26 - USE AMENDMENT FILED Type: IUAF

• 12/29/2019 - 4 years ago

  25 - CASE ASSIGNED TO INTENT TO USE PARALEGAL Type: AITU

• 12/18/2019 - 4 years ago

  24 - TEAS STATEMENT OF USE RECEIVED Type: EISU

• 8/13/2019 - 5 years ago

  23 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM

• 6/18/2019 - 5 years ago

  22 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 6/18/2019 - 5 years ago

  21 - PUBLISHED FOR OPPOSITION Type: PUBO

• 5/29/2019 - 5 years ago

  20 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 5/10/2019 - 5 years ago

  19 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 5/9/2019 - 5 years ago

  18 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 5/9/2019 - 5 years ago

  17 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 5/9/2019 - 5 years ago

  16 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 5/9/2019 - 5 years ago

  15 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 4/10/2019 - 5 years ago

  14 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN

• 4/10/2019 - 5 years ago

  13 - FINAL REFUSAL E-MAILED Type: GNFR

• 4/10/2019 - 5 years ago

  12 - FINAL REFUSAL WRITTEN Type: CNFR

• 2/19/2019 - 5 years ago

  11 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 2/19/2019 - 5 years ago

  10 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 2/18/2019 - 5 years ago

  9 - ASSIGNED TO LIE Type: ALIE

• 2/12/2019 - 5 years ago

  8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 10/27/2018 - 6 years ago

  7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 10/27/2018 - 6 years ago

  6 - NON-FINAL ACTION E-MAILED Type: GNRT

• 10/27/2018 - 6 years ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 10/25/2018 - 6 years ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 7/13/2018 - 6 years ago

  3 - NOTICE OF DESIGN SEARCH CODE E-MAILED Type: MDSC

• 7/12/2018 - 6 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS

• 7/10/2018 - 6 years ago

  1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP